Golfyeti,
Thanks for sharing. Sounds like these LDL-lowering anti-PCSK9 antibody therapies are doing quite well in the clinic. Lower LDL dramatically? Check. Decrease plaque volume? Check. Now we wait until early 2017 for the cardiovascular outcomes trial data. However, the big elephant in the room is the price tag.
BearDownAZ